Henry Schein revenue
Henry Schein's revenue was $13.18bn in fiscal 2025, up 4.0% on the year before. Since fiscal 2009 ($6.54bn) it has grown at a compound 4.5% a year. Over the last twelve months it was $13.73bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.5 | 7.5 | 8.5 | 8.9 | 9.6 | 10.4 | 10.6 | 11.6 | 12.5 | 13.2 | 10.0 | 10.1 | 12.4 | 12.6 | 12.3 | 12.7 | 13.2 | 13.7 |
| Growth on the year before | — | +15.1% | +13.3% | +4.8% | +6.9% | +8.5% | +2.5% | +8.9% | +7.7% | +5.9% | −24.4% | +1.3% | +22.6% | +2.0% | −2.4% | +2.7% | +4.0% | — |
| Gross profit | 1.9 | 2.2 | 2.4 | 2.5 | 2.7 | 2.9 | 3.0 | 3.2 | 2.7 | 2.9 | 3.1 | 2.8 | 3.7 | 3.8 | 3.9 | 4.0 | 4.1 | 4.3 |
| Gross margin | 29.3% | 28.8% | 28.3% | 28.0% | 27.8% | 28.1% | 28.3% | 27.9% | 22.0% | 22.0% | 31.0% | 27.8% | 29.6% | 30.3% | 31.3% | 31.7% | 31.1% | 31.6% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Global Distribution and Value Added Services | $11.1B | 84.3% | ▲ 3.6% |
| Global Specialty Products | $1.4B | 10.5% | ▲ 5.7% |
| Global Technology | $675M | 5.1% | ▲ 7.1% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $9.1B | 69.0% | ▲ 3.1% |
| Outside the US | $4.1B | 31.0% | ▲ 6.2% |
From Henry Schein's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Henry Schein | $13.73bn | 6.2% | 2.7% |
| 111, Inc. | $1.75bn | -12.7% | — |
| Cencora | $332.77bn | 5.1% | 9.4% |
| McKesson | $410.98bn | 8.8% | 13.1% |
| Cosmos Health Inc. | $73.7m | 33.8% | 14.8% |
| Cellyan Biotechnology Co., Ltd | $13.4m | -33.9% | — |
Compare with peers
- 111, Inc. revenue
- Cencora revenue
- McKesson revenue
- Cosmos Health Inc. revenue
- Cellyan Biotechnology Co., Ltd revenue
Head to head: HSIC vs YICOR vs HSICHSIC vs MCKCOSM vs HSIC
More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies